CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts.
Ashley Fraser presents on “MFN – Implications in Canada.”
U.S. Most-Favored-Nation (MFN) pricing proposals are creating uncertainty for pharmaceutical manufacturers, with potential implications beyond the U.S. This session will examine what these developments could mean for Canada, where reimbursement dynamics and international pricing considerations may influence pricing, access, and launch decisions.
The presentation will explore implications for established medicines and new launches, including launch timing, market availability, and commercial partnerships. Attendees will gain a clearer view of the key risks, strategic considerations, and signals Canadian stakeholders should monitor as international pricing policy evolves.
For more information on this event, click here.
